Krebsforschung

The Cancer Research theme encompasses companies advancing the prevention, detection, and treatment of malignancies across the oncology pipeline. Core tracks include oncology drug discovery and clinical development, immuno-oncology and cell/gene therapies, precision medicine with biomarkers and companion diagnostics, genomics and liquid biopsy, plus research tools, CROs, and enabling platforms.The sector's total market cap is 1076.66 billion USD, with a 24h change of +0.88%. Among 6 constituents, 5 are up (83.33%) and 1 are down (16.67%). The top gainer is Gilead Sciences Inc (GILD), with a 24h increase of +1.83%.Rangebound with leader-driven strength and mixed breadth. Favor quality innovators with near-term catalysts; buy pullbacks tactically and align medium-term exposure with earnings cadence and interest-rate trends.